• Publications
  • Influence
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
TLDR
Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition. Expand
Tumor characteristics and clinical outcome of elderly women with breast cancer.
TLDR
In women 55 years old or older, advancing age is associated with more favorable tumor biology, and breast cancer survival in older women is similar to survival in the general population irrespective of disease status. Expand
Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions*
TLDR
In conclusion, overexpression of FKHR dramatically inhibits the proliferation of ER-dependent MCF-7 breast cancer cells and represents a bifunctional NR intermediary protein that can act as either a coactivator or corepressor, depending on the receptor type. Expand
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas.
TLDR
The biologic phenotype of tubular and mucinous carcinomas is quite favorable and systemic adjuvant therapy and node dissection may be avoided in many patients with these special types of carcinoma. Expand
Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis
TLDR
Basaloid pattern confers a poor prognosis in nonsmall cell lung cancer, especially in stage I–II patients, suggesting that lung carcinoma with a basaloid pattern is not only a variant of squamous cell carcinomas or large cell carcinoma, but is a unique entity with a significantly poor prog outlook. Expand
Use of intensive care in patients with nonresectable lung cancer.
TLDR
Survival in nonsurgical patients with lung cancer requiring ICU admission was 37% after 90 days, and results provide additional evidence that ICU management may be appropriate in patients with nonresectable lung cancer and organ failure. Expand
Identification of germline 185delAG BRCA1 mutations in non‐Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado
TLDR
The authors observed a repeated occurrence of the 185delAG mutation (BRCA1; also known as 187delAG) in a non‐Jewish population that originated from the San Luis Valley in Colorado. Expand
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
TLDR
Cetuximab added to DOCOX may improve response rate minimally; there appears to be no improvement in progression-free survival, overall survival or 1-year survival. Expand
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
TLDR
The toxicities, recommended dose, and pharmacological profile of the TMZ/CDDP combination are determined and the recommended doses for Phase II clinical trials are TMZ 200 mg/m2/day for 5 days with 75 mg/ m2 CDDP on day 1, every 4 weeks. Expand
...
1
2
3
4
5
...